Who is sponsoring NCT04124731?

NCT04124731 is sponsored by Shanghai Chest Hospital.

What condition does NCT04124731 study?

NCT04124731 studies Carcinoma, Non-small Cell Lung Cancer.

What drugs are being tested in NCT04124731?

Interventions: sintilimab plus anlotinib, Chemotherapy.

What is the status of NCT04124731?

NCT04124731 is currently UNKNOWN.

Last reviewed 2019-10-10 · How we verify

SUNRISE: A Phase II Randomized Control Study of Sintilimab Combined With Anlotinib Versus Standard Platinum-based Chemotherapy as a First-line Treatment in Patients With Advanced NSCLC

NCT04124731 Phase 2 UNKNOWN

This is an open label, multi-center, randomized control phase II trial, to compare the efficacy and safety of sintilimab combined with anlotinib versus standard platinum-based chemotherapy as a first-line treatment in advanced NSCLC patients without driven-gene mutations.

Details

Lead sponsor	Shanghai Chest Hospital
Phase	Phase 2
Status	UNKNOWN
Enrolment	98
Start date	2019-10
Completion	2022-04

Conditions

Carcinoma
Non-small Cell Lung Cancer

Interventions

sintilimab plus anlotinib
Chemotherapy

Primary outcomes

Objective Respond Rate (ORR) — up to 24 months after enrollment or study close
ORR (per RECIST 1.1 as assessed by the investigator) is defined as the proportion (%) of patients with at least one visit response of complete response (CR) or partial response (PR).